GO Therapeutics

GO Therapeutics is a private, pre-clinical biotech founded in 2017 and based in Cambridge, MA, USA. The company is developing a proprietary discovery platform to identify novel, tumor-exclusive ('super-clean') antigen targets and therapeutic antibodies, primarily for solid tumors. By focusing on targets with minimal expression on healthy tissues, GO aims to unlock the full potential and improve the safety of advanced therapeutic modalities that have struggled in solid tumors due to target-related toxicity. The company appears to be in an early platform validation and asset discovery stage.

Proprietary discovery platform designed to identify novel, tumor-exclusive ('super-clean') antigen targets and generate therapeutic antibodies against them for use in advanced modalities like T-cell engagers, ADCs, and CAR-Ts.

GO Therapeutics competes in the novel cancer target discovery space with other biotech platforms (e.g., using proteomics, glycoproteomics, or AI/ML), as well as academic research institutions. Its key differentiator is the explicit focus on 'super-clean' targets for solid tumors. It also indirectly competes with companies developing their own proprietary targets for internal drug pipelines, though GO's partner-enabled model positions it as a potential supplier rather than a direct therapeutic developer.